Literature DB >> 21765036

Possible association of trisomy 8 with secondary pulmonary alveolar proteinosis in myelodysplastic syndrome.

Aya Nishida, Atsushi Miyamoto, Hisashi Yamamaoto, Naoyuki Uchida, Koji Izutsu, Atsushi Wake, Yasunori Ohta, Takeshi Fujii, Hideki Araoka, Shuichi Taniguchi, Kazuma Kishi.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21765036     DOI： 10.1164/ajrccm.184.2.279a

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Clinical features of secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome: Two case reports.

Authors:  Yin Liu; Lu Lu Chen; Yu Ying Qiu; Yong Long Xiao; Hou Rong Cai
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

2.  Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature.

Authors:  Can Chen; Xi-Lian Huang; Da-Quan Gao; Yi-Wei Li; Shen-Xian Qian
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

3.  Intestinal Behçet's disease complicated by myelodysplastic syndrome and secondary pulmonary alveolar proteinosis: a case report.

Authors:  Hiroshi Shimizu; Shuzo Sato; Tomohiro Suzuki; Tomomi Sasajima; Yosuke Takahata; Nobuhiko Shinohara; Kosuke Hideshima; Yuko Yokokawa; Nobuo Matsuhashi; Osamu Ichii; Mayumi Tai; Yutaka Ejiri; Kiori Yano; Takayuki Ikezoe; Hiromasa Ohira; Kiyoshi Migita
Journal:  BMC Gastroenterol       Date:  2021-12-20       Impact factor: 3.067

4.  Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan.

Authors:  Haruyuki Ishii; John F Seymour; Ryushi Tazawa; Yoshikazu Inoue; Naoyuki Uchida; Aya Nishida; Yoshihito Kogure; Takeshi Saraya; Keisuke Tomii; Toshinori Takada; Yuko Itoh; Masayuki Hojo; Toshio Ichiwata; Hajime Goto; Koh Nakata
Journal:  BMC Pulm Med       Date:  2014-03-05       Impact factor: 3.317
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.